Splisense
Founded 2017 · 16 employees on LinkedIn · 1 known investors
Find your way into Splisense
SpliSense develops antisense oligonucleotides (ASOs) — small synthetic RNA-binding molecules — designed using proprietary algorithms for therapeutic applications including splicing modulation and gene silencing. The company focuses on inhaled ASOs delivered directly to the lungs for treating pulmonary and obstructive lung diseases with minimal systemic exposure.
Investors · 1
Frequently asked questions
- What does Splisense do?
- SpliSense develops antisense oligonucleotides (ASOs) — small synthetic RNA-binding molecules — designed using proprietary algorithms for therapeutic applications including splicing modulation and gene silencing. The company focuses on inhaled ASOs delivered directly to the lungs for treating pulmonary and obstructive lung diseases with minimal systemic exposure.
- Who are Splisense's investors?
- Splisense's investors include Israel Biotech Fund.